Nilotinib Stada 200 Mg Cápsulas

Nilotinib, the active ingredient in Nilotinib Stada 200 Mg Cápsulas, is a tyrosine kinase inhibitor presented as a 200 mg capsule for oral use. It treats chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients. It is indicated for patients with the BCR‑ABL fusion gene driving disease progression.

GNH USA supplies Nilotinib Stada 200 Mg Cápsulas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product conforms to European Union quality standards and is manufactured under GMP conditions.

Nilotinib is a targeted therapy that inhibits the BCR‑ABL tyrosine kinase pathway in certain leukemias.

- Chronic myeloid leukemia (CML): Reduces disease progression and improves survival in patients with Philadelphia chromosome‑positive CML. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): Contributes to remission induction and disease control in adult patients with Ph+ ALL. - CML after prior therapy: Provides an alternative option for patients who are resistant or intolerant to first‑line tyrosine kinase inhibitors.

Common Side Effects: - Elevated liver enzymes - Nausea - Diarrhea - Fatigue

Serious or Rare Side Effects: - QT interval prolongation - Pancreatitis - Severe hepatic toxicity

Nilotinib requires careful monitoring and specific precautions: - Cardiac monitoring: Perform baseline ECG and periodic assessments due to risk of QT prolongation. - Hepatic function: Monitor liver enzymes regularly throughout therapy. - Electrolyte balance: Correct hypokalemia and hypomagnesemia before initiating treatment. - Drug interactions: Avoid concomitant use with strong CYP3A4 inhibitors. - Pregnancy and lactation: Use only if potential benefits justify the risk; safety not established. - Store at ambient temperature: Keep below 25 °C, in the original container, and protect from moisture.

Nilotinib has several notable drug interactions:

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase nilotinib exposure. - QT‑prolonging agents (e.g., amiodarone, sotalol): may exacerbate cardiac risk. - Antacids containing aluminum or magnesium: reduce absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may increase levels, requiring dose adjustment. - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Warfarin: may require closer INR monitoring.